Yuhan Corp. posts a sharp 55.7% year-on-year drop in Q3 operating profit to 24.1 billion won, falling short of market expectations and signaling earnings pressure in South Korea's pharmaceutical sector.
#YonhapInfomax #YuhanCorp #OperatingProfit #Q3Earnings #PharmaceuticalSector #EarningsMiss #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=89347
[Pharmaceutical & Bio Value-Up③] Daewoong's Treasury Shares Near 30%—Raising Concerns Over Shareholder Value 'Threat'
Daewoong Co.'s treasury shares approach 30%, the highest in South Korea's pharma sector, raising concerns among experts about governance risks and shareholder value dilution.
Yuhan Corporation's Q1 Operating Profit at 8.6 Billion Won - Below Expectations
Yuhan Corporation reports lower-than-anticipated Q1 operating profit of 8.6 billion won, signaling potential challenges in the pharmaceutical sector
Hanmi Pharm Q1 Operating Profit at 59 Billion Won - In Line with Expectations
Hanmi Pharmaceutical reports Q1 operating profit of 59 billion won, meeting market expectations and signaling steady performance in pharmaceutical sector
HanmiScience Q1 Operating Profit at 27 Billion Won, Down 27.4% Year-on-Year
HanmiScience reports significant decline in Q1 operating profit, reflecting challenging market conditions in pharmaceutical sector
Yonhap Infomax News